User menu

Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance®) in type 2 diabetes

Bibliographic reference Garber, A ; Cornes, M ; Lehert, Philippe ; Howlett, H. ; Marre, M.. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance®) in type 2 diabetes. In: Diabetes, Obesity and Metabolism, Vol. 5, p. 171-179 (2003)
Permanent URL http://hdl.handle.net/2078/21192
  1. New J. P., Hollis S., Campbell F., McDowell D., Burns E., Dornan T. L., Young R. J., Measuring clinical performance and outcomes from diabetes information systems: an observational study, 10.1007/s001250051458
  2. UK Prospective Diabetes Study Group., Lancet, 352, 837 (1998)
  3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), 10.1016/s0140-6736(98)07037-8
  4. Stratton I. M, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, 10.1136/bmj.321.7258.405
  5. Campbell IW, Br J Cardiol, 7, 625 (2000)
  6. Reasner CA, Br J Diabetes Vasc Dis, 2, 290 (2002)
  7. Turner Robert C., Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49), 10.1001/jama.281.21.2005
  8. DeFronzo Ralph A., Pharmacologic Therapy for Type 2 Diabetes Mellitus, 10.7326/0003-4819-131-4-199908170-00008
  9. Haupt E, Diabete Metabolisme (Paris), 27, 224 (1991)
  10. Hermann LS, Diabet Med, 11, 953 (1994)
  11. DeFronzo Ralph A., Goodman Anita M., Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus, 10.1056/nejm199508313330902
  12. Willms B., Ruge D., Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study, 10.1046/j.1464-5491.1999.00149.x
  13. Garber A. J., Larsen J., Schneider S. H., Piper B. A., Henry D., , Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes, 10.1046/j.1463-1326.2002.00211.x
  14. Marre M., Howlett H., Lehert P., Allavoine T., Improved glycaemic control with metformin-glibenclamide combined tablet therapy (GlucovanceR) in Type 2 diabetic patients inadequately controlled on metformin, 10.1046/j.1464-5491.2002.00774.x
  15. Blonde L, Rosenstock J, Mooradian A. D., Piper B-A., Henry D., Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy, 10.1046/j.1463-1326.2002.00229.x
  16. Simonson DC, Diabetes Care, 20, 597 (1997)
  17. Goldberg RB, The Glimepiride Protocol #201 Study Group Diabetes Care, 19, 849 (1996)
  18. Bailey CJ, Br J Cardiol, 7, 350 (2000)
  19. Turner R C, Millns H, Neil H A W, Stratton I M, Manley S E, Matthews D R, Holman R R, Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23), 10.1136/bmj.316.7134.823
  20. European Diabetes Policy Group 1999, A desktop guide to Type 2 diabetes mellitus, 10.1046/j.1464-5491.1999.00166.x
  21. American Diabetes Association., Diabetes Care, 22, S1 (1999)
  22. American Association of Clinical Endocrinologists., Endocrine Prac, 8, 40 (2002)
  23. Campbell I. W., Howlett H. C. S., Worldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysis, 10.1002/dmr.5610110509
  24. Paes AHP, Diabetes Care, 20, 1512 (1997)
  25. Morris AD, Diabetes, 49, A76 (2000)
  26. Melikian Caron, White T.Jeffrey, Vanderplas Ann, Dezii Christopher M., Chang Eunice, Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy, 10.1016/s0149-2918(02)85047-0